Clinical trial
A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects
NCT07903493 is registered in ClinicalTrials.gov with Mabsoft Therapeutics (Shanghai) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects
- Lead sponsor
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- November 30, 2026
- Completion date
- July 30, 2027
- Enrollment
- 32 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ankylosing spondylitis (as)
Arms
As registered; 5 arms.
-
MST-931 dose level 1 treatment Cohort
MST-931 dose level 1
-
MST-931 dose level 2 treatment Cohort
MST-931 dose level 2
-
MST-931 dose level 3 treatment Cohort
MST-931 dose level 3
-
MST-931 dose level 4 treatment Cohort
MST-931 dose level 4
-
Matching placebo for each dose group
Matching placebo
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Percentage of subjects with drug related adverse events (AEs)
Lead sponsor's other trials
Mabsoft Therapeutics (Shanghai) Co., Ltd., most recent start first.
Similar trials
Same condition (Spondylitis, Ankylosing) and phase, most recent start first.
+13 more trials See the condition page